Newbury Pharmaceuticals Q3: Slow traction - Redeye

Redeye provides a research update following the Q3 report recently published by Newbury. While the company continues to make progress in expanding its product portfolio and achieving regulatory approvals, the quarter was characterized by disappointing sales figures. However, as we believe this to be primarily attributed to postponed orders, we do not make any drastic changes to our estimates. We reiterate our base case valuation of SEK8.

Länk till analysen i sin helhet: https://www.redeye.se/research/1020769/newbury-pharmaceuticals-q3-slow-traction?utm_source=finwire&utm_medium=RSS